A Phase 2 Multicenter Single-arm Study to Assess the Safety Feasibility and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma | NYU Langone Health

A Phase 2 Multicenter Single-arm Study to Assess the Safety Feasibility and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Metastatic Melanoma
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1. Patients must have measurable metastatic melanoma 2. Patients must have undergone at least one prior systemic treatment for metastatic melanoma. 3. Patients must have progressive disease while receiving or after completion of most recent prior treatment.

You may not be eligible for this study if the following are true:

1. Patients who have received prior cell transfer therapy which included a non-myeloablative or myeloablative chemotherapy regimen. 2. Patients who have more than three brain metastases. 3. Patients who are pregnant or breastfeeding.